Published in Blood Weekly, March 23rd, 2006
This growth was broad-based and generated internally, reflecting strong sales growth from domestic and international markets, as well as from both ev3's cardio peripheral and neurovascular business segments.
For the fiscal year ended December 31, 2005, ev3's net sales were $133.7 million, an increase of 55% over net sales for fiscal 2004 of $86.3 million. Annual sales growth in 2005 also was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.